p53 immunoreactivity in non‐melanoma skin cancer from immunosuppressed and immunocompetent individuals: a comparative study of 246 tumours

Khorshid, S. M.; Glover, Mary; Churchill, Linda J.; McGregor, Jane; Proby, Charlotte M.

doi:10.1111/j.1600-0560.1996.tb01471.x

Cited by 14 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, studies using formalinfixed, paraffin embedded tissues seem to yield the highest percentage of anti-p53 positivity and more homogeneous results, even when only one anti-p53 antibody is used. 15 Consistent with the results of Khorshid 16 and McGregor, 17 we did not find statistically significant differences in p53 immunoreactivity in BCCs from RTRs and ICIs. However, in contrast to their reports, our study showed a higher prevalence of p53, and more extensive p53 immunoreactivity, in DEKs from RTRs compared to similar lesions from the general population.…”

Section: Discussionsupporting

confidence: 90%

“…However, in contrast to their reports, our study showed a higher prevalence of p53, and more extensive p53 immunoreactivity, in DEKs from RTRs compared to similar lesions from the general population. 16,17 Assuming that accumulation of p53 does, in fact, represent an important step in tumor progression, 18 it is possible that our results may indicate an easier progression of premalignant lesions to SCC in RTRs than in ICIs. This might explain the increased incidence of skin cancer in renal transplant recipients.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

P53 Immunohistochemical Expression in Early Posttransplant-Associated Malignant and Premalignant Cutaneous Lesions

Ferrándiz¹,

Fuente²,

Fernández‐Figueras³

et al. 1999

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 89%

P53 Immunohistochemical Expression in Early Posttransplant-Associated Malignant and Premalignant Cutaneous Lesions

Ferrándiz¹,

Fuente²,

Fernández‐Figueras³

et al. 1999

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…The p53 gene is intuitively suited to this process, inasmuch as it is the most frequently mutated locus in human malignancies in general [7,8,10]. Moreover, other tumors of the skin that are, like melanoma, thought to be related in part to ultraviolet solar damage to the skin-such as basal cell carcinoma and squamous carcinoma [59]-quite often manifest the presence of aberrant p53 protein. "Wild type" (native form) p53 gene productwhich serves an "antioncogene" function by preventing the replication of DNA-damaged cells-has a short intranuclear half-life and, therefore, cannot be labeled immunohistologically [10].…”

Section: Discussionmentioning

confidence: 99%

Immunohistologic Evaluation of Putatively Mutant p53 Protein in Cutaneous Melanocytic Neoplasms

Kaleem¹,

Lind²,

Humphrey³

et al. 1998

Int J Surg Pathol

View full text Add to dashboard Cite

Mutations in the p53 tumor suppressor gene, located at chromosomal locus 17pI3, are the most commonly seen genetic alterations found in human malignancies. Their role in the pathogenesis of malignant melanoma is thought to be limited, although variable results have been reported in reference to immunoreactivity for putatively mutant p53 protein (mp53) in melanocytic lesions in general. In that light, the authors undertook an immunohistologic evaluation of 256 well-characterized tumors in that category, including common nevi (CN; n=73); Spitz nevi (SN; n=40); nodular melanomas (NMMs; n=32), superficial spreading melanomas (SMMs; n=65); lentigo maligna melanomas (LMMs; n=23); and melanomas arising in preexisting nevi (MANs; n=23). One hundred cells were counted manually in randomly selected high-power microscopic fields, in regard to nuclear labeling for mp53. Results were recorded semiquantitatively, as negative, positive (1-4% of tumor cells); and positive (>5 % of tumor cells). No examples of CN or SN demonstrated any immunoreactivity whatever for mp53, whereas 105 of 143 melanomas (73%) did so. However, an mp53 index of >50% was seen in only 29% of the latter lesions. NMMs were most often mp53-positive and showed the highest numerical level of nuclear labeling, followed in respective order by SMMs, and LMMs/MANs. These results suggest that negative mp53-immunostaining cannot be equated with the diagnostic interpretation of a benign melanocytic neoplasm, because 27% of melanomas also failed to label for that determinant. However, the presence of mp53-immunolabeling in a melanocytic proliferation-even if at low levels-should conversely prompt careful consideration of melanoma as the favored diagnosis in the confined setting of morphologically difficult cases, inasmuch as no example of CN or SN in this series had that characteristic. Int J Surg Pathol 6(2): [73][74][75][76][77][78][79][80] 1998

show abstract

“…The p53 expression that is detected by the immunohistochemical method can be accepted as indirect indicator of mutation. Khorshid et al reported that finding p53 expression in more than 50% of tumor cells can be correlated with mutation (8). it is believed that p53 mutation develops in the early stages of skin carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

“…p53 has a half life of 6 to 30 minutes and is not normally seen in tissues while it has a longer half life and accumulates in the cell nucleus when it is mutated or activated. p53 expression detected with an immunohistochemical method can be accepted as an indirect indicator of the mutation (7,8).…”

Section: Introductionmentioning

confidence: 99%

The expression of p53 and cox-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases

Yalçın¹,

Seçkin²

2012

TJPATH

View full text Add to dashboard Cite

Objective: The aim of this study was to investigate p53 and CoX-2 expressions in basal cell carcinoma, squamous cell carcinoma and actinic keratoses, and to determine a possible relationship.Material and Method: 50 basal cell carcinoma, 45 squamous cell carcinoma and 45 actinic keratosis cases were evaluated. The type of tumor in basal cell carcinoma and tumor differentiation in squamous cell carcinoma were noted and the paraffin block that best represented the tumor was chosen. immunostaining by p53 and CoX-2 was performed on sections of the paraffin blocks.Results: p53 expression was observed in 98% of basal cell carcinoma, 88.9% of squamous cell carcinoma and all actinic keratosis cases. p53 expression was also noted in non-dysplastic appearing epithelium in actinic keratosis cases. CoX-2 expression was seen in 90, 100 and 88.9% of the basal cell carcinoma, squamous cell carcinoma and actinic keratosis groups, respectively. Skin appendages, inflammatory cells and vascular structures were also stained by CoX-2 besides tumor tissue. CoX-2 expression increased by the p53 expression increase in basal cell carcinoma and squamous cell carcinoma. p53 and CoX-2 expressions were not related in terms of tumor type in the BCC and were not related in terms of differentiation in SCC. Conclusion:The existence of p53 expression in actinic keratosis cases has supported the idea that p53 plays a role in the early steps of carcinogenesis in skin cancers. The fact that the expression of CoX-2 increases in line with the increase of p53 expression in basal cell carcinoma and squamous cell carcinoma cases indicates that CoX-2 expression may be affected by p53.Key Words: Basal cell carcinoma, Squamous cell carcinoma, actinic keratosis, p53, Cyclooxygenase 2 ÖZ Amaç: Çalışma bazal hücreli karsinom, skuamöz hücreli karsinom ve aktinik keratoz olgularında p53 ve CoX-2 ekspresyonlarını değerlendirmek ve aralarında ilişki olup olmadığını saptamak amacıyla planlandı. Gereç ve Yöntem:Çalışmaya 50 bazal hücreli karsinom, 45 skuamöz hücreli karsinom ve 45 aktinik keratoz olgusu dahil edildi. Bazal hücreli karsinom olgularında tümör tipleri, skuamöz hücreli karsinom olgularında tümör diferansiasyonları belirlenerek tümörü en iyi temsil eden parafin blok seçildi ve immünhistokimyasal yöntem ile p53 ve CoX-2 çalışıldı. Bulgular: p53 ekspresyonu bazal hücreli karsinom olgularının %98'inde, skuamöz hücreli karsinom olgularının %88,9'unda ve aktinik keratozlu olguların tamamında izlendi. aktinik keratoz olgularında hematoksilen-eosin kesitlerde displastik görünmeyen alanlarda da p53 ekspresyonu mevcuttu. CoX-2 ekspresyonu bazal hücreli karsinom grubunda %90, skuamöz hücreli karsinom grubunda %100, aktinik keratoz grubunda %88,9 oranında saptandı. CoX-2'nin ayrıca tümör dışında deri eklerinde, inflamatuvar hücrelerde ve vasküler yapılarda da eksprese olduğu gözlendi. Bazal hücreli karsinom ve skuamöz hücreli karsinom olgularında p53 ekspresyonu arttıkça CoX-2 ekspresyonunun da arttığı saptandı. p53 ve CoX-2'nin bazal hücreli karsinomda tüm...

show abstract

p53 immunoreactivity in non‐melanoma skin cancer from immunosuppressed and immunocompetent individuals: a comparative study of 246 tumours

Cited by 14 publications

References 26 publications

P53 Immunohistochemical Expression in Early Posttransplant-Associated Malignant and Premalignant Cutaneous Lesions

P53 Immunohistochemical Expression in Early Posttransplant-Associated Malignant and Premalignant Cutaneous Lesions

Immunohistologic Evaluation of Putatively Mutant p53 Protein in Cutaneous Melanocytic Neoplasms

The expression of p53 and cox-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases

Contact Info

Product

Resources

About